• Join our community!

    Do you have questions about celiac disease or the gluten-free diet?

  • Ads by Google:
     




    Get email alerts Subscribe to Celiac.com's FREE weekly eNewsletter

    Ads by Google:



       Get email alertsSubscribe to Celiac.com's FREE weekly eNewsletter

  • Member Statistics

    77,274
    Total Members
    3,093
    Most Online
    GFsista
    Newest Member
    GFsista
    Joined
  • 0

    What is Nanojuice, and How Can it Help Diagnose Celiac Disease?


    Jefferson Adams

    Celiac.com 08/01/2014 - I sometimes have to remind myself that it’s the 21st century, and that some amazing scientific breakthroughs that sound like something out of science fiction are, in fact, real.


    Ads by Google:




    ARTICLE CONTINUES BELOW ADS
    Ads by Google:



    Photo: Wikimedia Commons--ARSTake for example the technology, recently developed by researchers at the University at Buffalo, that allows researchers to safely examine intestines using nanoparticles. The popular name for these orally administered nanoparticles suspended in liquid is ‘Nanojuice.’

    Human small intestines are each about 23 feet long and 1 inch thick. Located between the stomach and the large intestine, the small intestine is notoriously difficult to examine, hence procedures like biopsies, endoscopies, etc.

    The new technique, being developed by researchers at the University at Buffalo, uses nanoparticles and lasers to image the organ. Once the nanoparticles reach the intestines, doctors can strike the particles with a harmless laser. The technique provides real-time view of the intestine. This will help doctors diagnose irritable bowel syndrome, celiac disease, Crohn's disease and other gastrointestinal illnesses, according to the researchers.

    So far, the research team has only tested their technology on mice, but they plan to refine the technique for clinical trials on human subjects. Researchers say that this method can help doctors get a better picture of the nature of celiac and other diseases.

    The study is published in the journal Nature Nanotechnology.

    What do you think? Will products like nanojuice represent the future of celiac disease diagnosis? If it is shown to be safe, would you prefer it to a biopsy?

    Source:

    0


    User Feedback

    Recommended Comments

    Guest Ann Sitchler

    Posted

    If safe, it would be better than invasive biopsy.

    Share this comment


    Link to comment
    Share on other sites
    Guest Elaine

    Posted

    If only celiac disease could be diagnosed for sure or not it would be so much better knowing if you had to be on the starvation diet.

    Share this comment


    Link to comment
    Share on other sites


    Your content will need to be approved by a moderator

    Guest
    You are commenting as a guest. If you have an account, please sign in.
    Add a comment...

    ×   Pasted as rich text.   Paste as plain text instead

      Only 75 emoji are allowed.

    ×   Your link has been automatically embedded.   Display as a link instead

    ×   Your previous content has been restored.   Clear editor

    ×   You cannot paste images directly. Upload or insert images from URL.


  • Popular Contributors

  • Ads by Google:

  • Who's Online   17 Members, 1 Anonymous, 1,128 Guests (See full list)

  • Related Articles

    Scott Adams
    The following was written by one of the CEDAR staff, Stephanie Tudor - TudorS@jove.uchsc.edu. Anyone with further questions should contact her directly. If you live in Denver and are biopsy-confirmed, they would love to hear from you.
    The Celiac Disease Autoimmunity Research (CEDAR) project is affiliated with the Department of Preventive Medicine and Biometrics in the School of Medicine of the University of Colorado, Health Sciences Center. It is a project supported by a grant from the National Institutes of Health (NIH), and will collect data for a total of five years. The principal investigator is Marian J. Rewers, MD, MPH, Ph.D. Other co-investigators include: Jill Norris, Ph.D.; George Eisenbarth, MD, Ph.D.; Ronald J. Sokol, MD; and Edward Hoffenberg, MD.
    The goals of this study are primarily to investigate the genetic and environmental causes of celiac disease, through the determination of the prevalence of anti-endomysial antibodies (EMA) in children considered to be at risk based on their family history (first degree relative) of either diabetes mellitus (Type I) or celiac disease or based on their HLA genotype (DR3) that is suspected to put them at an increased risk. The study is anticipating an enrollment of approximately 3,000 eligible children under the age of ten years. Most of the children reside in the Denver metro area, and a large proportion (approximately 40%) of the children involved with this research are concurrently enrolled in the Diabetes Autoimmunity Study in the Young (DAISY), which is run by the same principal investigator. The DAISY project is evaluating the presence of autoimmunity in relation to a pre-diabetic (insulin dependent diabetes mellitus) condition.
    The enrolled subjects are screened initially between the ages of two and five years of age with a serum sample tested using an IgA-based anti-endomysial antibody assay. The serum samples are also screened for IgA levels in order to rule out the potential for false negative results in IgA deficient children. For the subjects who are tested at a positive titration, follow-up includes a clinic evaluation and small bowel biopsy at the Pediatric Gastroenterology Department at the Childrens Hospital of Denver, Colorado. If a diagnosis of celiac is made, the subject is referred for nutritional counseling and follow-up serum testing is done six months after the diagnosis to confirm effective treatment. Dietary factors are also collected upon enrollment of the subjects, reflecting dietary changes that are made between the ages of one and two years of age, as the introduction of gluten into the diet usually occurs in this time frame. Information on family history of other autoimmune conditions is also collected. Subjects who test negative for the presence of anti-endomysial antibodies will be re-screened two years after their initial testing, to verify their immune status with respect to the anti-endomysial antibodies.
    By the end of the study period, we hope to have data that more accurately defines the prevalence of celiac disease in a United States population. The children recruited based on their HLA type are from a general population screening, and their data should be able to provide more accurate statistics on prevalence, and perhaps incidence, as some of these children have been followed since birth. We also hope to have identify associations with potential environmental exposures which may increase susceptibility to celiac disease.

    Scott Adams
    Celiac.com 01/31/2005 - SEOs (Search Engine Optimizers) are having a contest to see who will rank #1 in Google for the nonsense phrase "V7ndotcom elursrebmem" on May 15th, 2006 with a first prize of $7,000 and a 30 GByte iPod. With that much money at stake, SEOs world-wide are using all of their bags of tricks and strategies (including some nefarious black hat techniques) to "convince" Google that their web site should rank #1. But one underdog web site is giving these seasoned professionals one heck of a run for the money and trying to win that prize money for a good cause. www.watching-paint-dry.com will donate all contest winnings directly to charity -- specifically, the University of Maryland Center for Celiac Research (CFCR). And with a groundswell of interest, it just might win that $7,000 for Celiac Disease as countless web sites have taken notice and are already talking/linking to it a spontaneous grassroots effort to help out. In fact, this Press Release was handled by one cyberspace supporter who graciously volunteered (thank you "FrankB somewhere in the Canadian Rockies") to submit it.
    Three days into the contest, Google says (screenshot) there are 32,500 v7ndotcom elursrebmem web pages with the celiac charity site ranking #1. But can it retain that spot for 4 months to win the $7,000 -- stay tuned!
    While the person behind the V7ndotcom Elursrebmem for Charity web site wishes to remains anonymous, the web site states: "the reason Im doing this is because my two kids have Celiac Disease -- an intolerance of gluten ... and when my kids grow up, I would like to be able to go out and have a beer and pizza with them." The CFCR web site says: "we have worked with them before and are appreciative of their latest efforts to not only increase awareness about Celiac, but also raise funds for our research efforts."
    CFCR Operations Director Pam King adds: "This sounds like an interesting contest and the Center is pleased to be working again with a very committed person who cares deeply about his kids and helping us find a cure for celiac disease." CFCR Medical Director Dr. Fasano comments: "V7ndotcom elursrebmem sounds like a dreadful malady, but celiac disease is my top priority right now and every research dollar brings us one step closer to finding a cure for it."
    Web site owners can help out by linking to the V7ndotcom Elursrebmem for Charity web site by letting others know and adding a link to the V7ndotcom Elursrebmem for Charity site. You will be entered in the random drawing for that 30 GByte iPod being given away for the contest. And anyone can make a tax-deductible contribution to the CFCR now, by clicking on the donation button on the site.
    About University of Maryland Center for Celiac Research
    Is an institution engaged in clinical care, diagnostic support, education, and clinical and basic science research in Celiac Disease.
    Operations Director Pam King can be reached at (410) 706-8021 and/or pking@peds.umaryland.edu
    Resource Link: http://www.celiaccenter.org/seo_contest.asp

    Tina Turbin
    Celiac.com 10/12/2011 - According to recent estimates, three million Americans suffer from celiac disease—approximately 1% of the population, and only three percent of them have to this writing been correctly diagnosed. As startling as that sounds to us all, according to a news article on Medscape Today, the incidence of celiac disease has increased markedly over the last three decades, perhaps even as fourfold, and studies are suggesting the incidence may actually be higher than 1% of the population.
    What is the reason for this? According to Dr. Jonas Ludvigsson, MD, from the Department of Medicine, Epidemiology Unit at the Karolinska Institute and Orebro University Hospital in Sweden, and a renowned celiac expert, there may be many factors explaining this, but there probably is an actual increase underlying these.
    The Medscape article went on to report that the Mayo Clinic has confirmed increase in celiac disease incidence, reported in Discovery's Edge, the Mayo Clinic's research magazine. Dr. Joseph Murray, MD, and colleagues analyzed stored blood samples from Air Force recruits in the early 1950s for gluten antibodies. It was assumed that 1% would be positive, given today's estimates, but the number of positive results was far smaller. Dr. Murray and his colleagues compared their results with two more recently collected sets with the conclusion that celiac disease is about four times more common today than it was in the 1950s.
    Additionally, Dr. Ludviggon's research team in Sweden has found that those living with celiac disease and latent celiac disease have higher mortality than those who don't have these conditions. Latent celiac disease is also known as "gluten sensitivity," a term to describe those who have "normal small intestinal mucosa but positive celiac disease serology," estimated to affect 1 in 1000 people. According to Dr. Ludvigsson's research team, in 1 year, 10 of 1000 individuals with celiac disease will die, as compared with 7 in 1000 individuals without the disease. The mortality rate is increased among those who also have latent celiac disease as well. The increased risk, however, is quite small.
    As alarming as the statistics are regarding the increasing rate of celiac disease, Dr. Ludvigsson shares some good news with Medscape—the methods of diagnosing celiac disease are actually improving. According to some other estimates, the rate of celiac diagnosis rate is increasing. For those who are testing positive for the celiac disease, the only method of treatment currently available is eliminating gluten from the diet. Yes, this is a simple treatment, although it can require some challenging lifestyle adjustments for the gluten-free community, something which I address in my work as an author, researcher, and gluten-free advocate. In the future, we may see other treatments such as gluten-digesting enzymes (which are on the rise) or even the genetic modification of the structure of gluten in wheat so that it will not cause an autoimmune reaction in celiac patients. Even with celiac diagnosis incidence on the rise, with raised awareness and effective diagnosis, we can help change the lives of millions of celiac Americans for the better. This is an important endeavor.


    Jefferson Adams
    Celiac.com 06/26/2014 - Imagine being able to go to a party, or a restaurant, and test any food on your plate for gluten.
    A company called 6SensorLabs is developing a gluten sensor based on existing protein sensing technology that is already commercially available and proven to work. The company is looking to design a gluten test that can be used with all types of food.
    The portable test would work by placing a sample of food would be placed in a disposable pod and placing the pod in a sensor.
    Once activated, the device would tell you, in two minutes or less, if the food sample contained any gluten over the FDA standard of 20 ppm gluten or more.
    The sensor could also be used to detect gluten in any packaged foods.
    The sensor is designed to test a specific section of food on your plate, or a sauce, soup or liquid. It would not be able to detect traces of gluten that might be hiding somewhere else on your plate.
    While the product would have its limits in this respect, it would give users the ability to detect gluten in many cases.
    Would you want such a tool? Would it be helpful for you?

  • Recent Articles

    Jefferson Adams
    Celiac.com 06/16/2018 - Summer is the time for chips and salsa. This fresh salsa recipe relies on cabbage, yes, cabbage, as a secret ingredient. The cabbage brings a delicious flavor and helps the salsa hold together nicely for scooping with your favorite chips. The result is a fresh, tasty salsa that goes great with guacamole.
    Ingredients:
    3 cups ripe fresh tomatoes, diced 1 cup shredded green cabbage ½ cup diced yellow onion ¼ cup chopped fresh cilantro 1 jalapeno, seeded 1 Serrano pepper, seeded 2 tablespoons lemon juice 2 tablespoons red wine vinegar 2 garlic cloves, minced salt to taste black pepper, to taste Directions:
    Purée all ingredients together in a blender.
    Cover and refrigerate for at least 1 hour. 
    Adjust seasoning with salt and pepper, as desired. 
    Serve is a bowl with tortilla chips and guacamole.

    Dr. Ron Hoggan, Ed.D.
    Celiac.com 06/15/2018 - There seems to be widespread agreement in the published medical research reports that stuttering is driven by abnormalities in the brain. Sometimes these are the result of brain injuries resulting from a stroke. Other types of brain injuries can also result in stuttering. Patients with Parkinson’s disease who were treated with stimulation of the subthalamic nucleus, an area of the brain that regulates some motor functions, experienced a return or worsening of stuttering that improved when the stimulation was turned off (1). Similarly, stroke has also been reported in association with acquired stuttering (2). While there are some reports of psychological mechanisms underlying stuttering, a majority of reports seem to favor altered brain morphology and/or function as the root of stuttering (3). Reports of structural differences between the brain hemispheres that are absent in those who do not stutter are also common (4). About 5% of children stutter, beginning sometime around age 3, during the phase of speech acquisition. However, about 75% of these cases resolve without intervention, before reaching their teens (5). Some cases of aphasia, a loss of speech production or understanding, have been reported in association with damage or changes to one or more of the language centers of the brain (6). Stuttering may sometimes arise from changes or damage to these same language centers (7). Thus, many stutterers have abnormalities in the same regions of the brain similar to those seen in aphasia.
    So how, you may ask, is all this related to gluten? As a starting point, one report from the medical literature identifies a patient who developed aphasia after admission for severe diarrhea. By the time celiac disease was diagnosed, he had completely lost his faculty of speech. However, his speech and normal bowel function gradually returned after beginning a gluten free diet (8). This finding was so controversial at the time of publication (1988) that the authors chose to remain anonymous. Nonetheless, it is a valuable clue that suggests gluten as a factor in compromised speech production. At about the same time (late 1980’s) reports of connections between untreated celiac disease and seizures/epilepsy were emerging in the medical literature (9).
    With the advent of the Internet a whole new field of anecdotal information was emerging, connecting a variety of neurological symptoms to celiac disease. While many medical practitioners and researchers were casting aspersions on these assertions, a select few chose to explore such claims using scientific research designs and methods. While connections between stuttering and gluten consumption seem to have been overlooked by the medical research community, there is a rich literature on the Internet that cries out for more structured investigation of this connection. Conversely, perhaps a publication bias of the peer review process excludes work that explores this connection.
    Whatever the reason that stuttering has not been reported in the medical literature in association with gluten ingestion, a number of personal disclosures and comments suggesting a connection between gluten and stuttering can be found on the Internet. Abid Hussain, in an article about food allergy and stuttering said: “The most common food allergy prevalent in stutterers is that of gluten which has been found to aggravate the stutter” (10). Similarly, Craig Forsythe posted an article that includes five cases of self-reporting individuals who believe that their stuttering is or was connected to gluten, one of whom also experiences stuttering from foods containing yeast (11). The same site contains one report of a stutterer who has had no relief despite following a gluten free diet for 20 years (11). Another stutterer, Jay88, reports the complete disappearance of her/his stammer on a gluten free diet (12). Doubtless there are many more such anecdotes to be found on the Internet* but we have to question them, exercising more skepticism than we might when reading similar claims in a peer reviewed scientific or medical journal.
    There are many reports in such journals connecting brain and neurological ailments with gluten, so it is not much of a stretch, on that basis alone, to suspect that stuttering may be a symptom of the gluten syndrome. Rodney Ford has even characterized celiac disease as an ailment that may begin through gluten-induced neurological damage (13) and Marios Hadjivassiliou and his group of neurologists and neurological investigators have devoted considerable time and effort to research that reveals gluten as an important factor in a majority of neurological diseases of unknown origin (14) which, as I have pointed out previously, includes most neurological ailments.
    My own experience with stuttering is limited. I stuttered as a child when I became nervous, upset, or self-conscious. Although I have been gluten free for many years, I haven’t noticed any impact on my inclination to stutter when upset. I don’t know if they are related, but I have also had challenges with speaking when distressed and I have noticed a substantial improvement in this area since removing gluten from my diet. Nonetheless, I have long wondered if there is a connection between gluten consumption and stuttering. Having done the research for this article, I would now encourage stutterers to try a gluten free diet for six months to see if it will reduce or eliminate their stutter. Meanwhile, I hope that some investigator out there will research this matter, publish her findings, and start the ball rolling toward getting some definitive answers to this question.
    Sources:
    1. Toft M, Dietrichs E. Aggravated stuttering following subthalamic deep brain stimulation in Parkinson’s disease--two cases. BMC Neurol. 2011 Apr 8;11:44.
    2. Tani T, Sakai Y. Stuttering after right cerebellar infarction: a case study. J Fluency Disord. 2010 Jun;35(2):141-5. Epub 2010 Mar 15.
    3. Lundgren K, Helm-Estabrooks N, Klein R. Stuttering Following Acquired Brain Damage: A Review of the Literature. J Neurolinguistics. 2010 Sep 1;23(5):447-454.
    4. Jäncke L, Hänggi J, Steinmetz H. Morphological brain differences between adult stutterers and non-stutterers. BMC Neurol. 2004 Dec 10;4(1):23.
    5. Kell CA, Neumann K, von Kriegstein K, Posenenske C, von Gudenberg AW, Euler H, Giraud AL. How the brain repairs stuttering. Brain. 2009 Oct;132(Pt 10):2747-60. Epub 2009 Aug 26.
    6. Galantucci S, Tartaglia MC, Wilson SM, Henry ML, Filippi M, Agosta F, Dronkers NF, Henry RG, Ogar JM, Miller BL, Gorno-Tempini ML. White matter damage in primary progressive aphasias: a diffusion tensor tractography study. Brain. 2011 Jun 11.
    7. Lundgren K, Helm-Estabrooks N, Klein R. Stuttering Following Acquired Brain Damage: A Review of the Literature. J Neurolinguistics. 2010 Sep 1;23(5):447-454.
    8. [No authors listed] Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 43-1988. A 52-year-old man with persistent watery diarrhea and aphasia. N Engl J Med. 1988 Oct 27;319(17):1139-48
    9. Molteni N, Bardella MT, Baldassarri AR, Bianchi PA. Celiac disease associated with epilepsy and intracranial calcifications: report of two patients. Am J Gastroenterol. 1988 Sep;83(9):992-4.
    10. http://ezinearticles.com/?Food-Allergy-and-Stuttering-Link&id=1235725 
    11. http://www.craig.copperleife.com/health/stuttering_allergies.htm 
    12. https://www.celiac.com/forums/topic/73362-any-help-is-appreciated/
    13. Ford RP. The gluten syndrome: a neurological disease. Med Hypotheses. 2009 Sep;73(3):438-40. Epub 2009 Apr 29.
    14. Hadjivassiliou M, Gibson A, Davies-Jones GA, Lobo AJ, Stephenson TJ, Milford-Ward A. Does cryptic gluten sensitivity play a part in neurological illness? Lancet. 1996 Feb 10;347(8998):369-71.

    Jefferson Adams
    Celiac.com 06/14/2018 - Refractory celiac disease type II (RCDII) is a rare complication of celiac disease that has high death rates. To diagnose RCDII, doctors identify a clonal population of phenotypically aberrant intraepithelial lymphocytes (IELs). 
    However, researchers really don’t have much data regarding the frequency and significance of clonal T cell receptor (TCR) gene rearrangements (TCR-GRs) in small bowel (SB) biopsies of patients without RCDII. Such data could provide useful comparison information for patients with RCDII, among other things.
    To that end, a research team recently set out to try to get some information about the frequency and importance of clonal T cell receptor (TCR) gene rearrangements (TCR-GRs) in small bowel (SB) biopsies of patients without RCDII. The research team included Shafinaz Hussein, Tatyana Gindin, Stephen M Lagana, Carolina Arguelles-Grande, Suneeta Krishnareddy, Bachir Alobeid, Suzanne K Lewis, Mahesh M Mansukhani, Peter H R Green, and Govind Bhagat.
    They are variously affiliated with the Department of Pathology and Cell Biology, and the Department of Medicine at the Celiac Disease Center, New York Presbyterian Hospital/Columbia University Medical Center, New York, USA. Their team analyzed results of TCR-GR analyses performed on SB biopsies at our institution over a 3-year period, which were obtained from eight active celiac disease, 172 celiac disease on gluten-free diet, 33 RCDI, and three RCDII patients and 14 patients without celiac disease. 
    Clonal TCR-GRs are not infrequent in cases lacking features of RCDII, while PCPs are frequent in all disease phases. TCR-GR results should be assessed in conjunction with immunophenotypic, histological and clinical findings for appropriate diagnosis and classification of RCD.
    The team divided the TCR-GR patterns into clonal, polyclonal and prominent clonal peaks (PCPs), and correlated these patterns with clinical and pathological features. In all, they detected clonal TCR-GR products in biopsies from 67% of patients with RCDII, 17% of patients with RCDI and 6% of patients with gluten-free diet. They found PCPs in all disease phases, but saw no significant difference in the TCR-GR patterns between the non-RCDII disease categories (p=0.39). 
    They also noted a higher frequency of surface CD3(−) IELs in cases with clonal TCR-GR, but the PCP pattern showed no associations with any clinical or pathological feature. 
    Repeat biopsy showed that the clonal or PCP pattern persisted for up to 2 years with no evidence of RCDII. The study indicates that better understanding of clonal T cell receptor gene rearrangements may help researchers improve refractory celiac diagnosis. 
    Source:
    Journal of Clinical Pathologyhttp://dx.doi.org/10.1136/jclinpath-2018-205023

    Jefferson Adams
    Celiac.com 06/13/2018 - There have been numerous reports that olmesartan, aka Benicar, seems to trigger sprue‐like enteropathy in many patients, but so far, studies have produced mixed results, and there really hasn’t been a rigorous study of the issue. A team of researchers recently set out to assess whether olmesartan is associated with a higher rate of enteropathy compared with other angiotensin II receptor blockers (ARBs).
    The research team included Y.‐H. Dong; Y. Jin; TN Tsacogianis; M He; PH Hsieh; and JJ Gagne. They are variously affiliated with the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School in Boston, MA, USA; the Faculty of Pharmacy, School of Pharmaceutical Science at National Yang‐Ming University in Taipei, Taiwan; and the Department of Hepato‐Gastroenterology, Chi Mei Medical Center in Tainan, Taiwan.
    To get solid data on the issue, the team conducted a cohort study among ARB initiators in 5 US claims databases covering numerous health insurers. They used Cox regression models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for enteropathy‐related outcomes, including celiac disease, malabsorption, concomitant diagnoses of diarrhea and weight loss, and non‐infectious enteropathy. In all, they found nearly two million eligible patients. 
    They then assessed those patients and compared the results for olmesartan initiators to initiators of other ARBs after propensity score (PS) matching. They found unadjusted incidence rates of 0.82, 1.41, 1.66 and 29.20 per 1,000 person‐years for celiac disease, malabsorption, concomitant diagnoses of diarrhea and weight loss, and non‐infectious enteropathy respectively. 
    After PS matching comparing olmesartan to other ARBs, hazard ratios were 1.21 (95% CI, 1.05‐1.40), 1.00 (95% CI, 0.88‐1.13), 1.22 (95% CI, 1.10‐1.36) and 1.04 (95% CI, 1.01‐1.07) for each outcome. Patients aged 65 years and older showed greater hazard ratios for celiac disease, as did patients receiving treatment for more than 1 year, and patients receiving higher cumulative olmesartan doses.
    This is the first comprehensive multi‐database study to document a higher rate of enteropathy in olmesartan initiators as compared to initiators of other ARBs, though absolute rates were low for both groups.
    Source:
    Alimentary Pharmacology & Therapeutics

    Jefferson Adams
    Celiac.com 06/12/2018 - A life-long gluten-free diet is the only proven treatment for celiac disease. However, current methods for assessing gluten-free diet compliance are lack the sensitivity to detect occasional dietary transgressions that may cause gut mucosal damage. So, basically, there’s currently no good way to tell if celiac patients are suffering gut damage from low-level gluten contamination.
    A team of researchers recently set out to develop a method to determine gluten intake and monitor gluten-free dietary compliance in patients with celiac disease, and to determine its correlation with mucosal damage. The research team included ML Moreno, Á Cebolla, A Muñoz-Suano, C Carrillo-Carrion, I Comino, Á Pizarro, F León, A Rodríguez-Herrera, and C Sousa. They are variously affiliated with Facultad de Farmacia, Departamento de Microbiología y Parasitología, Universidad de Sevilla, Sevilla, Spain; Biomedal S.L., Sevilla, Spain; Unidad Clínica de Aparato Digestivo, Hospital Universitario Virgen del Rocío, Sevilla, Spain; Celimmune, Bethesda, Maryland, USA; and the Unidad de Gastroenterología y Nutrición, Instituto Hispalense de Pediatría, Sevilla, Spain.
    For their study, the team collected urine samples from 76 healthy subjects and 58 patients with celiac disease subjected to different gluten dietary conditions. To quantify gluten immunogenic peptides in solid-phase extracted urines, the team used a lateral flow test (LFT) with the highly sensitive and specific G12 monoclonal antibody for the most dominant GIPs and an LFT reader. 
    They detected GIPs in concentrated urines from healthy individuals previously subjected to gluten-free diet as early as 4-6 h after single gluten intake, and for 1-2 days afterward. The urine test showed gluten ingestion in about 50% of patients. Biopsy analysis showed that nearly 9 out of 10 celiac patients with no villous atrophy had no detectable GIP in urine, while all patients with quantifiable GIP in urine showed signs of gut damage.
    The ability to use GIP in urine to reveal gluten consumption will likely help lead to new and non-invasive methods for monitoring gluten-free diet compliance. The test is sensitive, specific and simple enough for clinical monitoring of celiac patients, as well as for basic and clinical research applications including drug development.
    Source:
    Gut. 2017 Feb;66(2):250-257.  doi: 10.1136/gutjnl-2015-310148.